Tebentafusp是新型雙特異性蛋白，由與抗CD3免疫效應功能融合的可溶性T細胞受體組成。Tebentafusp特異性靶向gp100（一種在黑色素細胞和黑色素瘤中表達的譜系抗原），旨在重定向和激活T細胞，以識別和殺死腫瘤細胞。

貨號:DHC27706
產品鏈接：http://www.atagenix.com/product_detail-75404.html
產品購買聯(lián)系方式：027-65279366
產品介紹：Tebentafusp (IMCgp100)是一種雙特異性融合蛋白，靶向gp100 (一種黑色素瘤相關抗原)。Tebentafusp通過高親和力T細胞受體(TCR)結合域和抗CD3 T細胞接合域引導T細胞殺死表達gp100的腫瘤細胞。Tebentafusp誘導炎性細胞因子和細胞溶解蛋白的產生，導致腫瘤細胞的直接裂解。
通用名:Tebentafusp
純度:>95% by SDS-PAGE.
濃度:1mg/ml
Formulationicon:0.01M PBS, pH 7.4.
內毒素:Please contact with the lab for this information.
別名:Bispecific fusion protein
靶點;物種:Human CD3E & TCR
種類:Humanized
受體鑒定:scFv-TR-BETA
CAS: 1874157-95-5
參考文獻：
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors. PMID: 35060440
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. PMID: 35254876
Antibodies to watch in 2022. PMID: 35030985
Tebentafusp for uveal melanoma. PMID: 34625736
Tebentafusp: a first-in-class treatment for metastatic uveal melanoma. PMID: 36970111
Uveal melanoma. PMID: 32273508
Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma. PMID: 36847626
Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma. PMID: 36199496
Tebentafusp in first-line melanoma trials: An outperforming outlier. PMID: 35364557
Antibodies to watch in 2023. PMID: 36472472
Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations. PMID: 36785760
Metastatic uveal melanoma: The final frontier. PMID: 34999237
T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities. PMID: 35880455
Tebentafusp als neuartige Immuntherapie zeigt einen überlebensvorteil beim metastasierten Uveamelanom und wird bereits in Deutschland eingesetzt. PMID: 35304951
A review of the cutaneous toxicities of tebentafusp-Featuring two cases involving superficial bullous reactions. PMID: 35510367
Advances in the clinical management of uveal melanoma. PMID: 36600005
Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment. PMID: 36931146
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study. PMID: 37286303
Recent Advances and Challenges in Uveal Melanoma Immunotherapy. PMID: 35804863
Drug-induced photosensitivity during tebentafusp treatment for metastatic uveal melanoma: A newly described occurrence. PMID: 36177547
[New drug approval: Tebentafusp for treatment of metastatic uveal melanoma HLA A*02:01-positive patients]. PMID: 36357199
Gp-100 as a Novel Therapeutic Target in Uveal Melanoma. PMID: 34885078
Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report. PMID: 37207136
Review of bi-specific therapies in uveal melanoma. PMID: 35236927
Evolving Management of Stage IV Melanoma. PMID: 37141553
TCR-Directed Therapy in the Treatment of Metastatic Uveal Melanoma. PMID: 35267523
First Drug Approved for Rare Eye Cancer. PMID: 35115315
Immunotherapies for the Treatment of Uveal Melanoma-History and Future. PMID: 31344957
Novel Approaches to the Systemic Management of Uveal Melanoma. PMID: 32725406
Combination strategies to durably suppress HIV-1: Soluble T cell receptors. PMID: 36065296
T cell engagers in solid tumors kick the door down. PMID: 34752755
Ensuring equity in the era of HLA-restricted cancer therapeutics. PMID: 36442912
Nail Apparatus Melanoma: Current Management and Future Perspectives. PMID: 36983205
TCR Bispecific Boosts Survival in Uveal Melanoma. PMID: 33839690
Novel TCR-based biologics: mobilising T cells to warm 'cold' tumours. PMID: 31207478
Treatment of metastatic uveal melanoma in 2022: improved treatment regimens and improved prognosis. PMID: 36094043
Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives. PMID: 34431316
Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors. PMID: 36710368
Redirecting Polyclonal T Cells against Cancer with Soluble T-Cell Receptors. PMID: 36255733
Hepatic Radiotherapy in Addition to Anti-PD-1 for the Treatment of Metastatic Uveal Melanoma Patients. PMID: 36672442
Pharmacological profile of novel anti-cancer drugs approved by USFDA in 2022: A Review. PMID: 37350009
Immunotherapy for ocular melanoma: a bibliometric and visualization analysis from 1991 to 2022. PMID: 37324010
Determinants of overall survival in patients with metastatic uveal melanoma. PMID: 37382208

黑色素瘤是皮膚癌中最嚴重的一種，發(fā)生于產生黑色素（賦予膚色的色素）的細胞（黑色素細胞）中。黑色素瘤也可能在您的眼睛中形成，罕見情況下可在您的身體內部形成，如在鼻或咽喉。

所有黑色素瘤的確切病因尚不清楚，但暴露于陽光或日光浴燈和日光浴床的紫外線（UV）輻射會增加患黑色素瘤的風險。限制?UV?照射有助于降低患黑色素瘤的風險。

40 歲以下的人，尤其是女性，患黑色素瘤的風險似乎正在升高。了解皮膚癌的預警信號，有助于確保在癌癥擴散之前發(fā)現(xiàn)癌變并進行治療。如果在早期發(fā)現(xiàn)，黑色素瘤是可以成功治療的。

黑色素瘤可能出現(xiàn)在您身體的任何部位。最常發(fā)生在陽光照射的部位，如背部、腿部、手臂和面部。

黑色素瘤也可能發(fā)生在陽光照射不多的區(qū)域，如腳底、手掌和指甲床。這些隱藏的黑色素瘤在膚色較深的人中更常見。

黑色素瘤的首發(fā)體征和癥狀通常為：

• 現(xiàn)有痣的改變

• 皮膚上出現(xiàn)新的色素沉著或外觀異常的生長物

黑色素瘤并不總是以痣開始。也可發(fā)生在其他外觀正常的皮膚上。